Paxlovid Dosing for 54-Year-Old Male with eGFR 85
This patient should receive the standard full dose of Paxlovid: nirmatrelvir 300 mg (two 150 mg tablets) with ritonavir 100 mg (one 100 mg tablet), taken together orally twice daily for 5 days.
Rationale
With an eGFR of 85 mL/min, this patient has mild renal impairment (eGFR 60-89 mL/min by standard classification). According to the FDA prescribing information, no dosage adjustment is recommended in patients with mild renal impairment (eGFR ≥60 to <90 mL/min) 1. The standard dosing regimen applies directly to this patient.
Dosing Specifications
- Nirmatrelvir: 300 mg (two 150 mg tablets)
- Ritonavir: 100 mg (one 100 mg tablet)
- Frequency: All 3 tablets taken together twice daily
- Duration: 5 days
- Timing: Can be taken with or without food 1
- Initiation: Should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset 1
Renal Function Thresholds to Remember
The FDA label provides clear cutoffs 1:
- eGFR ≥60 mL/min: Standard dose (300/100 mg twice daily)
- eGFR 30-59 mL/min (moderate impairment): Reduced dose (150/100 mg twice daily)
- eGFR <30 mL/min (severe impairment): Not recommended (though recent research suggests 300/100 mg loading dose followed by 150/100 mg once daily may be safe 2)
Critical Safety Considerations
Before prescribing, you must:
- Review all current medications for potential drug-drug interactions with ritonavir, a potent CYP3A4 inhibitor 1
- Check for contraindicated medications that are primarily metabolized by CYP3A4 where elevated concentrations could cause serious/life-threatening reactions 1
- Assess for strong CYP3A inducers that could reduce nirmatrelvir/ritonavir levels and lead to treatment failure 1
Common Pitfalls
- Don't underdose based on age alone: While older patients (>65 years) may achieve higher plasma concentrations 3, the FDA dosing is based on renal function, not age
- Don't confuse eGFR with creatinine clearance: The FDA label specifically uses eGFR thresholds for dosing decisions 1
- Don't forget the ritonavir component: Nirmatrelvir must be co-administered with ritonavir; failure to do so results in insufficient nirmatrelvir levels 1
Supporting Evidence
The WHO guidelines confirm that nirmatrelvir/ritonavir at 300/100 mg twice daily for 5 days is the standard regimen, with dose reduction to 150/100 mg twice daily only when eGFR is 30-59 mL/min 4. Recent pharmacokinetic studies demonstrate that standard dosing in patients with mild renal impairment achieves appropriate therapeutic levels without safety concerns 5.